Summary & Overview
HCPCS J9301: Obinutuzumab Injection, 10 mg
HCPCS Level II code J9301 identifies the administration unit for obinutuzumab (10 mg). As a biologic oncology drug frequently administered via infusion, accurate coding of J9301 is important for clinical documentation, claims processing, and national spend tracking. The code matters nationally given the high cost and utilization of monoclonal antibody therapies in oncology care.
Key payers referenced in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J9301 represents, typical sites of service where obinutuzumab is given, and the payer landscape covered. The publication provides benchmark perspectives, common billing considerations, and recent policy or coding guidance relevant to billing injectable oncology biologics.
The content is intended to help revenue cycle leaders, oncology clinic administrators, and policy analysts understand the clinical context and payer coverage environment for J9301. Data elements not provided in the input are noted as unavailable and are not inferred.
Billing Code Overview
HCPCS Level II code J9301 describes an injection of obinutuzumab, 10 mg. This code represents the drug administration unit for obinutuzumab measured per 10 milligrams and is used to report the administered drug itself.
-
Service type: Intravenous or subcutaneous biologic infusion/injection administered by a clinician
-
Typical site of service: Hospital outpatient department, physician office, or infusion center
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient with relapsed or refractory chronic lymphocytic leukemia (CLL) or follicular lymphoma presents to an outpatient infusion center for administration of monoclonal antibody therapy. The ordered medication is obinutuzumab dosed and billed as J9301 (injection, obinutuzumab, 10 mg). The clinical workflow includes pre-infusion nursing assessment (vitals, allergy check, IV access), verification of medication and dose by pharmacist and provider, premedication per protocol (acetaminophen, antihistamine, and corticosteroid as indicated), infusion administration via electronic pump with rate escalation per institutional protocol, monitoring for infusion-related reactions, documentation of administered dose and lot number, and post-infusion observation for delayed reactions. Typical site of service is an outpatient hospital infusion center or freestanding infusion clinic; administration may also occur in physician office-based infusion suites for oncology/hematology practices. Patients commonly have prior laboratory testing (CBC, CMP, and relevant tumor markers) and may receive combination chemotherapy or supportive care agents during the same visit per the treating oncologist's plan.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Billing for an office or outpatient visit | When reporting that the service was performed in an outpatient or office setting by the billing provider (institution-specific billing practices). |